Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Standard Chem & Pharm

TSEC:1720
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1720
TSEC
NT$6B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Standard Chem & Pharm CO., LTD. engages in the manufacture and sale of pharmaceutical products in Taiwan and internationally. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
1720 Share Price and Events
7 Day Returns
0.7%
TSEC:1720
3.1%
TW Pharmaceuticals
-0.2%
TW Market
1 Year Returns
6.2%
TSEC:1720
-22.5%
TW Pharmaceuticals
-10.7%
TW Market
1720 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Standard Chem & Pharm (1720) 0.7% -2.4% 4.8% 6.2% 4.5% -9.1%
TW Pharmaceuticals 3.1% -20.2% -19.4% -22.5% -29.8% -30.6%
TW Market -0.2% -14.9% -19.2% -10.7% -4.1% -0.7%
1 Year Return vs Industry and Market
  • 1720 outperformed the Pharmaceuticals industry which returned -22.5% over the past year.
  • 1720 outperformed the Market in Taiwan, Province of China which returned -10.7% over the past year.
Price Volatility
1720
Industry
5yr Volatility vs Market

Value

 Is Standard Chem & Pharm undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Standard Chem & Pharm to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Standard Chem & Pharm.

TSEC:1720 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6%
Perpetual Growth Rate 10-Year TW Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSEC:1720
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.2%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 20%) (16.37%))
0.85
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.71% + (0.85 * 6.21%)
5.99%

Discounted Cash Flow Calculation for TSEC:1720 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Standard Chem & Pharm is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

TSEC:1720 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 5.99%)
2020 355.89 Est @ -7.12% 335.79
2021 338.91 Est @ -4.77% 301.70
2022 328.32 Est @ -3.13% 275.76
2023 321.83 Est @ -1.98% 255.04
2024 318.07 Est @ -1.17% 237.82
2025 316.14 Est @ -0.61% 223.03
2026 315.47 Est @ -0.21% 209.99
2027 315.68 Est @ 0.07% 198.25
2028 316.50 Est @ 0.26% 187.54
2029 317.74 Est @ 0.39% 177.64
Present value of next 10 years cash flows NT$2,402.00
TSEC:1720 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$317.74 × (1 + 0.71%) ÷ (5.99% – 0.71%)
NT$6,063.86
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$6,063.86 ÷ (1 + 5.99%)10
NT$3,390.14
TSEC:1720 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$2,402.00 + NT$3,390.14
NT$5,792.14
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$5,792.14 / 178.70
NT$32.41
TSEC:1720 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$32.41
Current discount Discount to share price of NT$34.95
= -1 x (NT$34.95 - NT$32.41) / NT$32.41
-7.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Standard Chem & Pharm is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Standard Chem & Pharm's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Standard Chem & Pharm's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSEC:1720 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in TWD NT$2.11
TSEC:1720 Share Price ** TSEC (2020-04-06) in TWD NT$34.95
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 25 Publicly-Listed Pharmaceuticals Companies 19.14x
Taiwan, Province of China Market PE Ratio Median Figure of 1,474 Publicly-Listed Companies 14.01x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Standard Chem & Pharm.

TSEC:1720 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSEC:1720 Share Price ÷ EPS (both in TWD)

= 34.95 ÷ 2.11

16.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Standard Chem & Pharm is good value based on earnings compared to the TW Pharmaceuticals industry average.
  • Standard Chem & Pharm is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Standard Chem & Pharm's expected growth come at a high price?
Raw Data
TSEC:1720 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.87x
Taiwan, Province of China Market PEG Ratio Median Figure of 183 Publicly-Listed Companies 1.08x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Standard Chem & Pharm, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Standard Chem & Pharm's assets?
Raw Data
TSEC:1720 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in TWD NT$21.06
TSEC:1720 Share Price * TSEC (2020-04-06) in TWD NT$34.95
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 1.82x
Taiwan, Province of China Market PB Ratio Median Figure of 1,961 Publicly-Listed Companies 1.17x
TSEC:1720 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSEC:1720 Share Price ÷ Book Value per Share (both in TWD)

= 34.95 ÷ 21.06

1.66x

* Primary Listing of Standard Chem & Pharm.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Standard Chem & Pharm is good value based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess Standard Chem & Pharm's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Standard Chem & Pharm has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Standard Chem & Pharm expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.9%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Standard Chem & Pharm expected to grow at an attractive rate?
  • Unable to compare Standard Chem & Pharm's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Standard Chem & Pharm's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Standard Chem & Pharm's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSEC:1720 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 38.9%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 14.4%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSEC:1720 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSEC:1720 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 4,413 1
2020-04-06
TSEC:1720 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-12-31 3,937 638 376
2019-09-30 3,905 639 374
2019-06-30 3,769 673 383
2019-03-31 3,656 444 383
2018-12-31 3,573 485 374
2018-09-30 3,480 398 329
2018-06-30 3,624 525 366
2018-03-31 3,702 806 367
2017-12-31 3,849 709 363
2017-09-30 3,898 546 393
2017-06-30 3,761 327 347
2017-03-31 3,725 241 319

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Standard Chem & Pharm is high growth as no earnings estimate data is available.
  • Unable to determine if Standard Chem & Pharm is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSEC:1720 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Standard Chem & Pharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSEC:1720 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2020-04-06
TSEC:1720 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-12-31 2.11
2019-09-30 2.09
2019-06-30 2.14
2019-03-31 2.14
2018-12-31 2.09
2018-09-30 1.84
2018-06-30 2.05
2018-03-31 2.05
2017-12-31 2.03
2017-09-30 2.20
2017-06-30 1.94
2017-03-31 1.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Standard Chem & Pharm will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Standard Chem & Pharm's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Standard Chem & Pharm has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Standard Chem & Pharm performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Standard Chem & Pharm's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Standard Chem & Pharm's year on year earnings growth rate has been positive over the past 5 years.
  • Standard Chem & Pharm's 1-year earnings growth is less than its 5-year average (0.6% vs 1.5%)
  • Standard Chem & Pharm's earnings growth has not exceeded the TW Pharmaceuticals industry average in the past year (0.6% vs 1%).
Earnings and Revenue History
Standard Chem & Pharm's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Standard Chem & Pharm Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSEC:1720 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3,937.13 376.48 967.78 225.77
2019-09-30 3,904.68 373.63 980.73 229.32
2019-06-30 3,769.15 383.20 966.07 217.22
2019-03-31 3,656.01 383.21 954.61 216.03
2018-12-31 3,573.09 374.36 932.63 224.92
2018-09-30 3,480.13 329.14 927.18 227.63
2018-06-30 3,623.53 366.45 950.70 235.81
2018-03-31 3,702.01 367.16 941.78 248.47
2017-12-31 3,848.68 363.29 967.89 239.63
2017-09-30 3,897.74 392.82 941.92 252.11
2017-06-30 3,760.65 347.20 917.66 247.81
2017-03-31 3,724.71 318.96 935.47 242.85
2016-12-31 3,673.80 340.22 917.01 241.12
2016-09-30 3,635.30 337.91 931.20 250.02
2016-06-30 3,529.46 322.64 917.51 246.89
2016-03-31 3,373.82 325.31 875.65 237.74
2015-12-31 3,321.37 347.89 872.61 238.98
2015-09-30 3,280.03 345.18 890.11 220.60
2015-06-30 3,275.01 348.84 866.29 233.05
2015-03-31 3,304.05 381.07 853.01 238.86
2014-12-31 3,295.66 374.24 827.60 242.77
2014-09-30 3,203.19 334.42 803.47 253.17
2014-06-30 3,124.65 292.43 796.54 242.84
2014-03-31 3,068.55 277.00 822.79 235.11
2013-12-31 3,053.98 298.59 805.98 226.43
2013-09-30 3,207.27 331.42 808.69 217.81
2013-06-30 3,277.34 350.12 838.99 208.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Standard Chem & Pharm has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Standard Chem & Pharm used its assets more efficiently than the TW Pharmaceuticals industry average last year based on Return on Assets.
  • Standard Chem & Pharm has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Standard Chem & Pharm's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Standard Chem & Pharm has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Standard Chem & Pharm's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Standard Chem & Pharm's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Standard Chem & Pharm is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Standard Chem & Pharm's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Standard Chem & Pharm's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Standard Chem & Pharm Company Filings, last reported 3 months ago.

TSEC:1720 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 4,646.42 865.00 1,692.17
2019-09-30 4,294.57 1,178.49 1,617.41
2019-06-30 4,126.88 699.80 1,328.03
2019-03-31 4,324.67 946.06 1,554.61
2018-12-31 4,246.31 947.31 1,450.55
2018-09-30 4,178.97 933.56 1,221.70
2018-06-30 4,069.92 924.81 1,392.16
2018-03-31 4,252.15 896.06 1,490.90
2017-12-31 4,202.19 937.30 1,405.16
2017-09-30 4,208.82 938.53 1,296.97
2017-06-30 4,067.18 759.75 1,215.28
2017-03-31 4,221.84 760.97 1,128.69
2016-12-31 4,196.66 622.67 1,163.75
2016-09-30 4,081.43 598.37 1,107.92
2016-06-30 3,819.58 271.20 907.60
2016-03-31 3,994.07 359.89 956.97
2015-12-31 3,886.92 330.49 936.50
2015-09-30 3,742.29 432.47 807.58
2015-06-30 3,626.43 339.49 852.28
2015-03-31 3,716.08 365.50 759.03
2014-12-31 3,605.75 379.71 722.83
2014-09-30 3,467.41 628.92 871.81
2014-06-30 3,389.57 428.46 1,077.93
2014-03-31 3,696.42 435.59 1,086.75
2013-12-31 3,582.46 462.20 1,011.33
2013-09-30 3,491.62 302.20 968.26
2013-06-30 3,306.94 372.78 1,101.95
  • Standard Chem & Pharm's level of debt (18.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.5% vs 18.6% today).
  • Debt is well covered by operating cash flow (73.8%, greater than 20% of total debt).
  • Standard Chem & Pharm earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Standard Chem & Pharm's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Standard Chem & Pharm has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Standard Chem & Pharm's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.29%
Current annual income from Standard Chem & Pharm dividends.
If you bought NT$2,000 of Standard Chem & Pharm shares you are expected to receive NT$86 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Standard Chem & Pharm's pays a higher dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (3.25%).
  • Standard Chem & Pharm's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (6.93%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSEC:1720 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 3.2%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1330 Stocks 4.6%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.8%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 3.2%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSEC:1720 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2020-04-06
TSEC:1720 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2020-03-26 1.500 4.340
2020-03-25 1.500 4.718
2019-07-16 1.500 4.556
2018-07-17 1.600 4.982
2017-06-16 1.500 4.408
2016-07-15 1.500 4.573
2015-05-12 1.000 3.008
2015-03-30 1.000 2.686
2014-03-28 2.500 6.310
2013-03-27 1.200 3.098
2012-10-30 1.000 3.763
2012-08-30 1.000 3.912
2012-05-14 1.000 4.089
2011-05-13 0.467 1.872
2011-05-03 0.467 1.552
2010-04-30 1.495 5.260
2010-01-15 1.495 5.997
2009-04-29 1.089 4.169
2009-04-27 1.089 4.300

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Standard Chem & Pharm's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.4x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Standard Chem & Pharm's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Standard Chem & Pharm afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Standard Chem & Pharm has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Standard Chem & Pharm's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tzu-Ting Fan
TENURE AS CEO 11.8 years
CEO Bio

Tzu-Ting Fan serves as General Manger and Director of Standard Chem. & Pharm. Co., Ltd. and its President since July 1, 2008. Tzu-Ting Fan serves as Representative of Corporate Director of Syn-Tech Chem. & Pharm. Co., Ltd. and Syngen Biotech Co., Ltd. Tzu-Ting Fan holds a Master of Science in Computer Science, University of California.

CEO Compensation
  • Insufficient data for Tzu-Ting to compare compensation growth.
  • Insufficient data for Tzu-Ting to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the Standard Chem & Pharm management team in years:

11.8
Average Tenure
  • The average tenure for the Standard Chem & Pharm management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chin-Tsai Fan

TITLE
Chairman & GM

Tzu-Ting Fan

TITLE
President
TENURE
11.8 yrs

Reynold Hsu

TITLE
Finance Manager
TENURE
1.3 yrs

Wei-Jen Chen

TITLE
Vice President
TENURE
19 yrs
Board of Directors

Chin-Tsai Fan

TITLE
Chairman & GM

Tzu-Ting Fan

TITLE
President

Yuan-Teh Lee

TITLE
Director

Hwei-Jiung Wang

TITLE
Independent Director

Lin-Yu Lee

TITLE
Independent Director

Yuan-Fong Kao

TITLE
Supervisor

Tsuey-Wen Yeh

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Standard Chem & Pharm's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Standard Chem & Pharm has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Standard Chem & Pharm CO., LTD. engages in the manufacture and sale of pharmaceutical products in Taiwan and internationally. It offers various pharmaceutical products, including circulatory system, digestive system, respiratory system, antihistamine, metabolism, anti-microbial, and skin and mucous membrane drugs; and C.N.S drugs, such as antipyretics and analgesics, anxiolytics and sedatives, antidepressants, tranquilizers, skeletal muscle relaxants, and anticonvulsants. The company also provides nutritional supplements for hospitals and clinics; and APIs for use in human and veterinary drugs for various pharmaceutical companies. In addition, it develops and sells various formulae milk powders and health supplements for infants, adults, and elders under the brands, such as Angel, Neoangelac plus, Stronzon, etc. The company was founded in 1967 and is headquartered in Tainan City, Taiwan.

Details
Name: Standard Chem & Pharm CO., LTD.
1720
Exchange: TSEC
Founded: 1967
NT$6,245,425,200
178,696,000
Website: http://www.standard.com.tw
Address: Standard Chem & Pharm CO., LTD.
No.6-20, Tuku,
Tuku Village,
Tainan City,
73055,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSEC 1720 Common Stock Taiwan Stock Exchange TW TWD 20. Dec 1995
Number of employees
Current staff
Staff numbers
0
Standard Chem & Pharm employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 16:09
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.